[ad_1]
Jakarta, CNBC Indonesia – Not many know, it turns out that China has completed the final phase of clinical trials of the Covid-19 vaccine conducted by Sinovac Biotech, CanSino Biological and Sinopharm.
This was announced by the General Director of Disease Prevention and Control of the Ministry of Health (Kemenkes) Achmad Yurianto in a talk show about the update of the Covid-19 Vaccine, on Monday (9/19/2020).
According to Achmad Yurianto, Sinovac has completed its final phase clinical trials in several countries, including Brazil and China. In Indonesia, the final clinical trial will be completed in December 2020.
Sinopharm has already completed its end-stage clinical trials in the United Arab Emirates (UAE) and Turkey. As for CanSino, it has completed its end-stage clinical trials in Canada, China, and Saudi Arabia, and several other countries have issued Emergency Use Authorization (USA) permits.
The vaccines made by the three Chinese pharmaceutical companies have also received an emergency use permit from the Chinese government to inject into those at the forefront and groups of people in urgent need.
Achmad Yurianto revealed that Sinovac will ship 1.5 million doses of vaccine next year and 1.5 million vaccines in December 2020.
“The characteristics of dual use of Sinovac, each person has two injections for 1.5 million people,” he said.
Meanwhile, Sinopharm will ship 15 million doses of vaccine. It is also a two-shot vaccine for one person, so 7.5 million people receive this vaccine.
Whereas CanSino single dose means that it is injected once per person. CanSino is ready to ship 100,000 doses of vaccine this year.
“In November and December we have confirmed the availability of vaccines for 9.1 million people,” said Achmad Yurianto.
(Roy / Roy)
